SG11202102930YA - Interleukin 10 conjugates and uses thereof - Google Patents

Interleukin 10 conjugates and uses thereof

Info

Publication number
SG11202102930YA
SG11202102930YA SG11202102930YA SG11202102930YA SG11202102930YA SG 11202102930Y A SG11202102930Y A SG 11202102930YA SG 11202102930Y A SG11202102930Y A SG 11202102930YA SG 11202102930Y A SG11202102930Y A SG 11202102930YA SG 11202102930Y A SG11202102930Y A SG 11202102930YA
Authority
SG
Singapore
Prior art keywords
conjugates
interleukin
Prior art date
Application number
SG11202102930YA
Other languages
English (en)
Inventor
Carolina E Caffaro
Jerod Ptacin
Marcos Milla
Original Assignee
Synthorx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthorx Inc filed Critical Synthorx Inc
Publication of SG11202102930YA publication Critical patent/SG11202102930YA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/5428IL-10
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
SG11202102930YA 2018-11-08 2019-11-07 Interleukin 10 conjugates and uses thereof SG11202102930YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862757690P 2018-11-08 2018-11-08
US201962911036P 2019-10-04 2019-10-04
PCT/US2019/060261 WO2020097325A1 (en) 2018-11-08 2019-11-07 Interleukin 10 conjugates and uses thereof

Publications (1)

Publication Number Publication Date
SG11202102930YA true SG11202102930YA (en) 2021-04-29

Family

ID=70612119

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202102930YA SG11202102930YA (en) 2018-11-08 2019-11-07 Interleukin 10 conjugates and uses thereof

Country Status (16)

Country Link
US (1) US20210338829A1 (es)
EP (1) EP3876973A4 (es)
JP (1) JP2022506531A (es)
KR (1) KR20210091170A (es)
CN (1) CN113260374A (es)
AU (1) AU2019376076A1 (es)
BR (1) BR112021005401A2 (es)
CA (1) CA3117572A1 (es)
CO (1) CO2021003530A2 (es)
IL (1) IL282736A (es)
MA (1) MA54195A (es)
MX (1) MX2021005293A (es)
PH (1) PH12021550611A1 (es)
SG (1) SG11202102930YA (es)
TW (1) TW202031284A (es)
WO (1) WO2020097325A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018309166B2 (en) 2017-08-03 2022-12-08 Synthorx, Inc. Cytokine conjugates for the treatment of proliferative and infectious diseases
WO2019165453A1 (en) 2018-02-26 2019-08-29 Synthorx, Inc. Il-15 conjugates and uses thereof
SG11202107354WA (en) 2019-02-06 2021-08-30 Synthorx Inc Il-2 conjugates and methods of use thereof
CH716227B1 (it) * 2020-04-16 2020-11-30 Contrad Swiss Sa Composizione in gel per applicazione topica per la riduzione dell'infiammazione locale.
JP2023548045A (ja) 2020-10-23 2023-11-15 アッシャー バイオセラピューティクス, インコーポレイテッド 免疫細胞機能をモジュレートするためのcd8抗原結合分子を有する融合物
AU2021396247A1 (en) * 2020-12-09 2023-07-06 Asher Biotherapeutics, Inc. Fusions of mutant interleukin-10 polypeptides with antigen binding molecules for modulating immune cell function
CN112618699A (zh) * 2020-12-31 2021-04-09 深圳先进技术研究院 一种能够提供治疗有效量的白介素10的试剂及其抗肿瘤应用
KR20240024235A (ko) * 2021-07-29 2024-02-23 노보코덱스 바이오파마슈티컬즈 컴퍼니 리미티드 비천연 아미노산, 및 이의 용도, 이를 함유하는 재조합 단백질, 및 재조합 단백질 컨주게이트

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004044006A1 (en) * 2002-11-14 2004-05-27 Maxygen, Inc. Conjugates of interleukin-10 and polymers
EP1610825A2 (en) * 2003-03-31 2006-01-04 Xencor, Inc. Methods for rational pegylation of proteins
WO2013130913A1 (en) * 2012-02-29 2013-09-06 Ambrx, Inc. Interleukin-10 polypeptide conjugates and their uses
ES2688206T3 (es) * 2013-06-17 2018-10-31 Armo Biosciences, Inc. Procedimiento de evaluación de la identidad y la estabilidad de proteínas
EP3341012A4 (en) * 2015-08-25 2019-03-20 Armo Biosciences, Inc. METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
CN113366015A (zh) * 2018-10-19 2021-09-07 Ambrx公司 白细胞介素-10多肽缀合物、其二聚体及其用途

Also Published As

Publication number Publication date
EP3876973A1 (en) 2021-09-15
KR20210091170A (ko) 2021-07-21
US20210338829A1 (en) 2021-11-04
IL282736A (en) 2021-06-30
PH12021550611A1 (en) 2021-10-04
MA54195A (fr) 2022-02-16
EP3876973A4 (en) 2022-08-03
TW202031284A (zh) 2020-09-01
MX2021005293A (es) 2021-06-23
CA3117572A1 (en) 2020-05-14
AU2019376076A1 (en) 2021-04-15
WO2020097325A1 (en) 2020-05-14
JP2022506531A (ja) 2022-01-17
CO2021003530A2 (es) 2021-04-19
CN113260374A (zh) 2021-08-13
BR112021005401A2 (pt) 2021-06-29

Similar Documents

Publication Publication Date Title
EP3854806A4 (en) NEW INTERLEUKIN 2 AND ASSOCIATED USE
IL282736A (en) Interleukin 10 conjugates and their use
IL279897A (en) Fusosome preparations and their uses
IL276827A (en) IL-15 conjugates and their use
IL281192A (en) Interleukin-2 polypeptide conjugates and uses thereof
SG11202011015QA (en) Fusosome compositions and uses thereof
EP3854805A4 (en) NOVEL INTERLEUKIN 2 AND ITS USE
SG11202101517PA (en) Isoquinoline-steroid conjugates and uses thereof
IL290141A (en) Formulations of anti-pvrig antibodies and uses thereof
IL312612A (en) Senolytic preparations and their uses
IL286847A (en) hsp90-binding couplers and formulations thereof
IL283942A (en) Tubulysins and protein-tubulysin conjugation
IL277791A (en) HSP90 targeting conjugates and their formulations
ZA202005144B (en) Parenteral formulations and uses thereof
IL290301A (en) Pairings of il-15 and their use
IL277663A (en) Arunumab preparations and their uses
SG11202009242RA (en) Short conjugated oligoelectrolytes and uses thereof
GB201807576D0 (en) Compositions and uses thereof
GB201821138D0 (en) Compositions and uses thereof
GB201812334D0 (en) Compositions and uses thereof
GB201821144D0 (en) Compositions and uses thereof
GB201819493D0 (en) Compositions and uses thereof
GB201818495D0 (en) Compositions and uses thereof
GB201818375D0 (en) Compositions and uses thereof
GB201815546D0 (en) Composition and uses thereof